Sildenafil Citrate Tablet, Film Coated
Product Images NDC 68071-3862

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 68071-3862). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 3862 9)

Pdp (68071 3862 9)
This text contains information about a medication called Sildenafil 100mg, including details about its lot number, manufacturer's label, expiration date, and serial number. It also provides guidelines on reporting side effects to the FDA and emphasizes storing the medication at a controlled temperature range of 68-77°F.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This text provides data on Systolic Blood Pressure measurements in mmHg at different time points pre-dose and post-dose for SILDENAFIL 100mg and PLACEBO. It indicates readings at various time intervals and can be used for analyzing the impact of the medication on blood pressure.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This is a comparison showing the change in systolic blood pressure (SBP) in mmHG over time postdose. The first column represents the values for Doxazosin + Placebo, while the second column represents Doxazosin + Sildenafil 50 mg. The time points from 1.000 to 8.000 hours postdose are evaluated for the change in SBP.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This text provides information about a clinical study comparing the effects of Doxazosin + Sildenafil 100 mg and Doxazosin + Placebo. The study likely includes measurements taken at different time points after dosing. Additionally, the units mentioned are likely mmHg, which typically refer to blood pressure measurements.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This text provides data on plasma concentrations (ng/mL) over time post-dose (in hours) for a commercial tablet treatment. The concentrations are listed at various time points after administration.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
This text provides the percentage of patients at the endpoint, starting from 80% and gradually decreasing to 1%. It also mentions the baseline score, which can be used as a reference point for further analysis.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
This text is showing the percentage of patients reporting improvement for different dosages of placebo and sildenafil citrate. The percentages are shown for 25mg, 50mg, and 100mg doses of sildenafil citrate compared to a placebo. The data includes the number of patients in each group.*
FDA Label Image

Image Description (Torrent Logo Copy)

Image Description (Torrent Logo Copy)
FDA Label Image
Image Description (Torrent Logo)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.